Status:
WITHDRAWN
SPECTAbrain: Screening Patients With Brain Tumors for Efficient Clinical Trial Access
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Conditions:
Brain Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
The SPECTAbrain protocol describes a structure for screening patients with brain tumors to efficiently allocate eligible patients in relevant therapeutic biomarker-driven clinical trials. Efficiency i...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Pathologically confirmed newly diagnosed primary CNS tumors, with a focus on diffuse gliomas of grades II, III and IV, meningiomas from patients who are candidates for pharmacotherapy, and rare CNS tumors;
- Availability of adequate Human Biological Material (HBM): FFPE tissue sample from the primary and/or recurrent tumor and/or metastasis, obtained at the time of surgery or biopsy; minimal amount requested is detailed in the HBM guidelines. Inclusion of samples taken at any recurrence diagnosed during follow-up is strongly encouraged but optional;
- At least three months life expectancy;
- Written informed consent according to ICH/GCP and national/local regulations;
- Absence of exclusion criteria, such as active hepatitis B/C or HIV, second malignancies, severe organ dysfunction, or other comorbidities that will prevent inclusion into clinical trials.
Exclusion
Key Trial Info
Start Date :
May 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2019
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02307604
Start Date
May 1 2016
End Date
January 1 2019
Last Update
June 24 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Lille
Lille, France, FR 59037
2
Assistance Publique - Hopitaux de Paris - La Pitie Salpetriere
Paris, France, FR 75651